Ulcerative Colitis | Unmet Need | US/EU | 2021
Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs, where available) are the mainstay of biological treatment for moderate to severe ulcerative colitis (UC). However, these agents carry safety risks and have efficacy limitations. Takeda’s Entyvio (a cell adhesion molecule [CAM] inhibitor), Pfizer’s Xeljanz / Xeljanz XR (an oral Janus-activated kinase [JAK] inhibitor), and Janssen’s Stelara (an interleukin [IL]-12/23 inhibitor) have expanded the treatment options for moderate to severe UC, but significant unmet need remains, especially in the treatment of UC patients refractory to these therapies. Several agents in late-phase development, including additional JAK inhibitors, S1P-R modulators, and IL-23 inhibitors, are poised to enter the moderate to severe UC market over the next several years, but whether they will be able to fulfill the unmet need remains to be seen.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for moderate to severe UC?
- How do TNF-α inhibitors (branded and biosimilars) and other targeted therapies (i.e., Entyvio, Stelara, and Xeljanz / Xeljanz XR) perform on treatment drivers and goals?
- In addition to efficacy, what other drug attributes influence physician prescribing behavior the most, and which attributes have a limited impact?
- What are the prevailing areas of high unmet need and hidden opportunity in moderate to severe UC?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European gastroenterologists for a hypothetical new UC drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European gastroenterologists fielded in March 2021
Key companies: AbbVie, Janssen, Takeda, Pfizer, Eli Lilly, Bristol Myers Squibb
Key drugs: Humira, Remicade, Entyvio, Xeljanz / Xeljanz XR, Stelara, Remsima SC, adalimumab biosimilar
